 |
|
Experts Debate Drugs for Healthy Women With Breast Cancer Risk
Joan Stephenson
JAMA. 1999;282:117-118.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Atlanta—For some time, anxiety and "watchful waiting" have been the usual prescription for women with an elevated risk of developing breast cancer. Now, however, a working group convened by the nation's largest group of cancer specialists cautiously suggests that physicians consider offering a risk-reduction measure—the drug tamoxifen—to healthy women age 35 and older who have an increased risk of developing the disease.
But this advice, presented in a new report unveiled at the annual meeting of the American Society of Clinical Oncology (ASCO), fell far short of a ringing endorsement of prescribing tamoxifen for healthy women.
| |
Photo credit: American Society of Clinical Oncology
|
|
| |
A nasal spray containing IM862, an experimental antiangiogenesis agent designed to "starve" tumors by inhibiting the formation of blood vessels needed to support tumor growth, showed encouraging results in a small study involving patients with Kaposi sarcoma. A research team led by Parkash Gill, . . . [Full Text of this Article] |
|
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Estrogen, Anti-Estrogen, and Gender: Differences in Methamphetamine Neurotoxicity
DLUZEN and McDERMOTT
Ann. N. Y. Acad. Sci. 2002;965:136-156.
ABSTRACT
| FULL TEXT
|
